Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1479-5876

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies ; volume:14 ; number:1 ; day:10 ; month:6 ; year:2016 ; pages:1-12 ; date:12.2016
Journal of translational medicine ; 14, Heft 1 (10.6.2016), 1-12, 12.2016

Creator: Sun, Woo Young

Contributor: Lee, Yu Kyung
Koo, Ja Seung
SpringerLink (Online service)

DOI: 10.1186/s12967-016-0925-6

URN: urn:nbn:de:1111-20160612466

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:46 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Sun, Woo Young
Lee, Yu Kyung
Koo, Ja Seung
SpringerLink (Online service)

Other Objects (12)

The risk of PD-L1 expression misclassification in triple-negative breast cancer

PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer

Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil

Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer

Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer

Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort

PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer

Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients

Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers

The risk of PD-L1 expression misclassification in triple-negative breast cancer

PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer

Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil

Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer

Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer

Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort

PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer

Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients

Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers

The risk of PD-L1 expression misclassification in triple-negative breast cancer

PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer

Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil

Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer

Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer

Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort

PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer

Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients

Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

The risk of PD-L1 expression misclassification in triple-negative breast cancer

PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer

Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil

Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer

Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer

Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort

PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer

Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients

Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers

The risk of PD-L1 expression misclassification in triple-negative breast cancer

PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer

Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil

Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer

Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer

Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort

PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer

Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients

Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers

The risk of PD-L1 expression misclassification in triple-negative breast cancer

PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer

Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil

Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer

Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer

Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort

PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer

Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients

Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers

Related objects

Reset password